×
About 3,168 results

ALLMedicine™ Polycythemia Vera Center

Research & Reviews  1,016 results

Pacritinib: First Approval.
https://doi.org/10.1007/s40265-022-01718-y 10.1007/s11899-020-00596-z 10.2217/fon.15.200 10.2147/JEP.S110702 10.1038/leu.2011.148 10.2147/JEP.S150729 10.1186/s13045-016-0367-x 10.2174/1872312809666150119105250 10.1001/jamaoncol.2017.5818 10.1016/S2352-3026(17)30027-3 10.3324/haematol.2021.279415 10.1182/bloodadvances.2020003314 10.1182/blood-2013-02-484832 10.1158/1078-0432.CCR-20-4725
Drugs Lamb YN

May 15th, 2022 - Pacritinib (VONJO™) is an orally administered, small molecule kinase inhibitor being developed by CTI BioPharma for the treatment of myelofibrosis and graft-versus-host disease. Pacritinib received its first approval in February 2022 in the USA fo...

Extended Access of Momelotinib in Adults With Myelofibrosis
https://clinicaltrials.gov/ct2/show/NCT03441113

May 13th, 2022 - The primary objective of this study is to provide extended access and assess long-term safety of momelotinib (MMB) in participants with primary myelofibrosis (PMF) or post-polycythemia vera or post-essential thrombocythemia myelofibrosis (Post-PV/...

Hemorrhages in polycythemia vera and essential thrombocythemia: epidemiology, descripti...
https://doi.org/10.1055/a-1849-8477
Thrombosis and Haemostasis; Nicol C, Ajzenberg N et. al.

May 12th, 2022 - The management of myeloproliferative neoplasms (MPN) is based on the reduction of thrombosis risk. The incidence, impact, and risk factors of bleedings have been less studied. All patients with polycythemia vera (n=339) or essential thrombocythemi...

Study to Evaluate Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation and Expansion Study of PXS-5505 in Patients With Primary, Post-polycythemia Vera or Post-essential Thrombocythemia Myel...
https://clinicaltrials.gov/ct2/show/NCT04676529

May 11th, 2022 - The study consists of two phases: a dose escalation phase and a cohort expansion phase. The dose escalation phase will follow a 3+3 design with a starting dose of 100 mg twice daily, and a treatment duration of 4 weeks. Patients will be able to pa...

An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or...
https://clinicaltrials.gov/ct2/show/NCT04485260

May 9th, 2022 - This is a phase 1b/2 study of KRT-232 combined with ruxolitinib in subjects with MF who have a suboptimal response after at least 18 weeks of treatment with ruxolitinib. The primary objective of the study is to determine a recommended phase 2 dose...

see more →

Guidelines  3 results

NCCN Guidelines Insights: Myeloproliferative Neoplasms, Version 2.2018.
https://doi.org/10.6004/jnccn.2017.0157
Journal of the National Comprehensive Cancer Network : JN... Mesa RA, Jamieson C et. al.

Oct 7th, 2017 - Myeloproliferative neoplasms (MPNs) are a group of heterogeneous disorders of the hematopoietic system that include myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET). PV and ET are characterized by significant thromboh...

Myeloproliferative Neoplasms, Version 2.2017, NCCN Clinical Practice Guidelines in Onco...
https://doi.org/10.6004/jnccn.2016.0169
Journal of the National Comprehensive Cancer Network : JN... Mesa R, Jamieson C et. al.

Dec 14th, 2016 - Myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET) are a group of heterogeneous disorders of the hematopoietic system collectively known as Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs). The diagn...

Prophylaxis and management of venous thromboembolism in patients with myeloproliferativ...
https://doi.org/10.1007/s00277-014-2224-8
Annals of Hematology; Kreher S, Ochsenreither S et. al.

Oct 14th, 2014 - Patients with Philadelphia chromosome-negative myeloproliferative neoplasms (MPN) like polycythemia vera and essential thrombocythemia are at increased risk of arterial and venous thrombosis. Strategies of prevention may consist of platelet aggreg...

see more →

Drugs  10 results see all →

Clinicaltrials.gov  48 results

Extended Access of Momelotinib in Adults With Myelofibrosis
https://clinicaltrials.gov/ct2/show/NCT03441113

May 13th, 2022 - The primary objective of this study is to provide extended access and assess long-term safety of momelotinib (MMB) in participants with primary myelofibrosis (PMF) or post-polycythemia vera or post-essential thrombocythemia myelofibrosis (Post-PV/...

Study to Evaluate Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation and Expansion Study of PXS-5505 in Patients With Primary, Post-polycythemia Vera or Post-essential Thrombocythemia Myel...
https://clinicaltrials.gov/ct2/show/NCT04676529

May 11th, 2022 - The study consists of two phases: a dose escalation phase and a cohort expansion phase. The dose escalation phase will follow a 3+3 design with a starting dose of 100 mg twice daily, and a treatment duration of 4 weeks. Patients will be able to pa...

An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or...
https://clinicaltrials.gov/ct2/show/NCT04485260

May 9th, 2022 - This is a phase 1b/2 study of KRT-232 combined with ruxolitinib in subjects with MF who have a suboptimal response after at least 18 weeks of treatment with ruxolitinib. The primary objective of the study is to determine a recommended phase 2 dose...

A Study of Low Dose Interferon Alpha Versus Hydroxyurea in Treatment of Chronic Myeloid Neoplasms
https://clinicaltrials.gov/ct2/show/NCT01387763

Apr 27th, 2022 - Chronic myeloid neoplasms (CMPN) consists of three main entities, polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF). These three disorders have many overlapping clinical features. The diseases are clonal stem c...

IMG-7289 in Patients With Essential Thrombocythemia (ET) or Polycythemia Vera (PV)
https://clinicaltrials.gov/ct2/show/NCT04262141

Apr 14th, 2022 - The purpose of this study is to assess the hematologic effects of IMG-7289 therapy in ET and PV patients who require platelet, White Blood Cell (WBC) or Red Blood Cell (RBC) control, and have failed at least one standard therapy.

see more →

News  186 results

Review of New Drugs That May Be Used During Pregnancy
https://www.medscape.com/viewarticle/972789

Apr 27th, 2022 - In 2021, the Food and Drug Administration approved 50 new drugs, but 24 will not be described here because they would probably not be used in pregnancy. The 24 are Aduhelm (aducanumab) to treat Alzheimer’s disease; Azstarys (serdexmethylphenidate ...

Review of new drugs that may be used during pregnancy
https://www.mdedge.com/obgyn/article/254158/obstetrics/review-new-drugs-may-be-used-during-pregnancy
Gerald G. Briggs, BPharm, FCCP

Apr 26th, 2022 - In 2021, the Food and Drug Administration approved 50 new drugs, but 24 will not be described here because they would probably not be used in pregnancy. The 24 are Aduhelm (aducanumab) to treat Alzheimer’s disease; Azstarys (serdexmethylphenidate.

Pacritinib Paves a “Unique Lane” of Treatment for Select Myelofibrosis
https://www.onclive.com/view/pacritinib-paves-a-unique-lane-of-treatment-for-select-myelofibrosis

Apr 5th, 2022 - Patients who develop post–essential thrombocythemia myelofibrosis (PET-MF) or post–polycythemia vera myelofibrosis (PPV-MF), which are associated with significant symptom burden and bone marrow failure, have limited therapies available for effecti...

NCCN Recommends Ropeginterferon Alfa-2b in Clinical Practice Guidelines Update
https://www.onclive.com/view/nccn-recommends-ropeginterferon-alfa-2b-in-clinical-practice-guidelines-update

Mar 24th, 2022 - The National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology has been revised to include ropeginterferon alfa-2b-njft (Besremi) as a recommended treatment option for adult patients with polycythemia vera, according to ...

Clinical Presentation of Subacute Combined Degeneration in a Patient With Chronic B12 Deficiency
https://www.mdedge.com/fedprac/article/252920/neurology/clinical-presentation-subacute-combined-degeneration-patient
Nathan Kostick, Evan Chen et. al.

Mar 21st, 2022 - Subacute combined degeneration (SCD) is an acquired neurologic complication of vitamin B12 (cobalamin) or, rarely, vitamin B9 (folate) deficiency. SCD is characterized by progressive demyelination of the dorsal and lateral spinal cord, resulting i.

see more →

Patient Education  4 results see all →